$ELDN
Eledon Pharmaceuticals, Inc.

2017 Q3 Form 10-Q Financial Statement

#000119312517252847 Filed on August 09, 2017

View on sec.gov

Income Statement

Concept 2017 Q3 2017 Q2 2016 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.450M $6.130M $2.720M
YoY Change -22.22% 66.58% -18.56%
% of Gross Profit
Research & Development $517.0K $533.0K $1.040M
YoY Change -91.61% -9.97% -86.55%
% of Gross Profit
Depreciation & Amortization $0.00 $0.00 $20.00K
YoY Change -100.0% -100.0% -66.67%
% of Gross Profit
Operating Expenses $2.965M $6.666M $3.760M
YoY Change -68.15% 615.24% -66.03%
Operating Profit -$2.965M -$6.666M -$3.760M
YoY Change -68.15% 615.24% -66.04%
Interest Expense $20.00K
YoY Change -66.67%
% of Operating Profit
Other Income/Expense, Net -$5.000K $4.000K
YoY Change -105.71%
Pretax Income -$2.970M -$6.660M -$3.740M
YoY Change -67.96% -50.78% -66.06%
Income Tax
% Of Pretax Income
Net Earnings -$2.970M -$6.662M -$3.737M
YoY Change -67.96% 564.87% -66.08%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$7.615M -$28.96M -$26.71M
COMMON SHARES
Basic Shares Outstanding 6.943M shares 22.64M shares 22.64M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q3 2017 Q2 2016 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $19.10M $22.50M $27.40M
YoY Change -44.96% -48.75% -57.19%
Cash & Equivalents $19.09M $22.50M $1.103M
Short-Term Investments $4.200M
Other Short-Term Assets $1.900M $2.300M $33.00K
YoY Change 18.75% 0.0% -98.97%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $21.00M $24.84M $1.150M
YoY Change -42.2% -46.21% -98.29%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00 $49.00K $31.00K
YoY Change -100.0% -87.78% -93.66%
Goodwill $1.867M
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $100.0K $15.00K $15.00K
YoY Change -66.67% -95.0% -66.67%
Total Long-Term Assets $2.000M $2.001M $46.00K
YoY Change 416.8% 198.21% -94.28%
TOTAL ASSETS
Total Short-Term Assets $21.00M $24.84M $1.150M
Total Long-Term Assets $2.000M $2.001M $46.00K
Total Assets $23.00M $26.84M $1.196M
YoY Change -37.37% -42.71% -98.24%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $200.0K $374.0K $338.0K
YoY Change -77.43% -79.74% -72.02%
Accrued Expenses $2.100M $1.486M $113.0K
YoY Change -61.52% -75.11% -97.72%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.306M $3.160M $3.898M
YoY Change -63.65% -59.58% -36.74%
LONG-TERM LIABILITIES
Long-Term Debt $100.0K $200.0K $100.0K
YoY Change 0.0% 0.0% 0.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $94.00K $245.0K $84.00K
YoY Change -21.67% 57.05% -4.55%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.306M $3.160M $3.898M
Total Long-Term Liabilities $94.00K $245.0K $84.00K
Total Liabilities $2.400M $3.405M $3.898M
YoY Change -62.87% -57.29% -37.63%
SHAREHOLDERS EQUITY
Retained Earnings -$22.43M -$14.39M
YoY Change -85.66% -89.05%
Common Stock $7.000K $45.87M $11.39M
YoY Change -100.0% -76.51% -94.11%
Preferred Stock $291.0K
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $20.60M $23.44M -$2.702M
YoY Change
Total Liabilities & Shareholders Equity $23.00M $26.84M $1.196M
YoY Change -37.37% -42.71% -98.24%

Cashflow Statement

Concept 2017 Q3 2017 Q2 2016 Q4
OPERATING ACTIVITIES
Net Income -$2.970M -$6.662M -$3.737M
YoY Change -67.96% 564.87% -66.08%
Depreciation, Depletion And Amortization $0.00 $0.00 $20.00K
YoY Change -100.0% -100.0% -66.67%
Cash From Operating Activities -$3.420M -$5.760M -$7.310M
YoY Change -62.7% -44.08% -17.68%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $18.93M $11.90M
YoY Change -100.0% 132.27% -12000.0%
Cash From Investing Activities $0.00 $18.93M $11.90M
YoY Change -100.0% 132.27% -3818.75%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 7.120M 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -3.420M -5.760M -7.310M
Cash From Investing Activities 0.000 18.93M 11.90M
Cash From Financing Activities 0.000 7.120M 0.000
Net Change In Cash -3.420M 20.29M 4.590M
YoY Change -152.78% -1043.72% -150.11%
FREE CASH FLOW
Cash From Operating Activities -$3.420M -$5.760M -$7.310M
Capital Expenditures $0.00
Free Cash Flow -$7.310M
YoY Change -15.59%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q2 us-gaap Assets
Assets
26844000
CY2017Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22498000
CY2017Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
22581000
CY2017Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2017Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6943832 shares
CY2017Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0010
CY2017Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
6943060 shares
CY2016Q3 us-gaap Debt Instrument Fair Value
DebtInstrumentFairValue
3400000
CY2016Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
937000
CY2017Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
1486000
CY2017Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1486000
CY2017Q2 us-gaap Accrued Vacation Current
AccruedVacationCurrent
122000
CY2017Q2 us-gaap Assets Current
AssetsCurrent
24843000
CY2017Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
276000
CY2017Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
45858000
CY2017Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
374000
CY2017Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6943832 shares
CY2017Q2 us-gaap Common Stock Value
CommonStockValue
7000
CY2017Q2 us-gaap Convertible Debt
ConvertibleDebt
0
CY2017Q2 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2017Q2 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2017Q2 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2017Q2 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2017Q2 us-gaap Guarantee Obligations Current Carrying Value
GuaranteeObligationsCurrentCarryingValue
0
CY2017Q2 us-gaap Goodwill
Goodwill
1867000
CY2017Q2 us-gaap Liabilities
Liabilities
3405000
CY2017Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
26844000
CY2017Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
245000
CY2017Q2 us-gaap Liabilities Current
LiabilitiesCurrent
3160000
CY2017Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
221000
CY2017Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
15000
CY2017Q2 us-gaap Postemployment Benefits Liability Current
PostemploymentBenefitsLiabilityCurrent
1300000
CY2017Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0010
CY2017Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2017Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2332000
CY2017Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
49000
CY2017Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
13000
CY2017Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
70000
CY2017Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-22426000
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2016Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
3447000
CY2017Q2 us-gaap Stockholders Equity
StockholdersEquity
23439000
CY2016Q4 us-gaap Liabilities
Liabilities
3898000
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1196000
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3898000
CY2016Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
3447000
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
12000
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
15000
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0026
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
6565540 shares
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
11000
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
33000
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
452706 shares
CY2017Q2 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
349000
CY2017Q2 nvus Contingent Liability
ContingentLiability
0
CY2017Q2 nvus Working Capital
WorkingCapital
21700000
CY2017Q2 nvus Accrued Clinical Current
AccruedClinicalCurrent
518000
CY2015Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3109000
CY2016Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
113000
CY2016Q4 us-gaap Additional Paid In Capital Preferred Stock
AdditionalPaidInCapitalPreferredStock
291000
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
113000
CY2016Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
50000
CY2016Q4 us-gaap Assets Current
AssetsCurrent
1150000
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
11385000
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
338000
CY2016Q4 us-gaap Assets
Assets
1196000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1103000
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1117000
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
9207060 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
82246 shares
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0026
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
82246 shares
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
452706 shares
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
31000
CY2016Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
14000
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-14390000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
-2702000
CY2016Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
51000
CY2017Q2 us-gaap Stock Issued During Period Shares Reverse Stock Splits
StockIssuedDuringPeriodSharesReverseStockSplits
836857 shares
CY2016Q3 nvus Percentage Of Discount On Common Stock
PercentageOfDiscountOnCommonStock
0.15 pure
dei Amendment Flag
AmendmentFlag
false
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
236000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
587819 shares
us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-6890000
us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
7700000
us-gaap Business Acquisitions Pro Forma Income Loss From Continuing Operations Before Changes In Accounting And Extraordinary Items Net Of Tax
BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax
-6945000
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
23250000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
21464000
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap Depreciation And Amortization
DepreciationAndAmortization
16000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.51
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2017-06-30
dei Entity Registrant Name
EntityRegistrantName
Novus Therapeutics, Inc.
dei Entity Central Index Key
EntityCentralIndexKey
0001404281
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
3072000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-31000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7039000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
7000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1167000
us-gaap Liabilities Assumed1
LiabilitiesAssumed1
2947000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
182000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
23258000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-8913000
us-gaap Operating Expenses
OperatingExpenses
8051000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
7119000
us-gaap Net Income Loss
NetIncomeLoss
-8036000
us-gaap Operating Income Loss
OperatingIncomeLoss
-8051000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
15000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4000000
us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
8000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
3119000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1012000
dei Trading Symbol
TradingSymbol
NVUS
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2270907 shares
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Use of Estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of the Company&#x2019;s financial statements in conformity with GAAP requires management to make informed estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company&#x2019;s financial statements and accompanying notes. The most significant estimates in the Company&#x2019;s financial statements relate to the valuation of certain financial instruments, stock-based compensation, and accruals for liabilities and other matters that affect the condensed consolidated financial statements and related disclosures. Actual results could differ materially from those estimates under different assumptions or conditions and the differences may be material to the consolidated financial statements.</p> </div>
nvus Business Acquisition Pro Forma Operating Expenses
BusinessAcquisitionProFormaOperatingExpenses
6945000
nvus Conversion Of Preferred Stock To Common Stock
ConversionOfPreferredStockToCommonStock
9000
nvus Business Acquisitions Pro Forma Weighted Average Shares Outstanding Basic And Diluted
BusinessAcquisitionsProFormaWeightedAverageSharesOutstandingBasicAndDiluted
6943831 shares
nvus Number Of Milestones Achieved
NumberOfMilestonesAchieved
0 Milestone
nvus Business Acquisition Pro Forma Income Loss From Continuing Operations Before Changes In Accounting And Extraordinary Items Net Of Tax Per Share Basic And Diluted
BusinessAcquisitionProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTaxPerShareBasicAndDiluted
-0.99
nvus Conversion Of Promissory Notes And Interest To Common Stock
ConversionOfPromissoryNotesAndInterestToCommonStock
3447000
nvus Fair Value Of Assets Acquired And Liabilities Assumed In Merger
FairValueOfAssetsAcquiredAndLiabilitiesAssumedInMerger
125000
nvus Interest Accumulated On Preferred Shares And Contingently Issuable For Little Or No Cash
InterestAccumulatedOnPreferredSharesAndContingentlyIssuableForLittleOrNoCash
328000
nvus Net Income Loss Attributable To Shareholders Of Preferred Shares And Contingently Issuable For Little Or No Cash
NetIncomeLossAttributableToShareholdersOfPreferredSharesAndContingentlyIssuableForLittleOrNoCash
2666000
nvus Conversion Of Contingently Issuable Shares To Common Stock
ConversionOfContingentlyIssuableSharesToCommonStock
291000
nvus Net Loss Used In The Calculation Of Basic And Diluted Loss Per Share
NetLossUsedInTheCalculationOfBasicAndDilutedLossPerShare
-5698000
nvus Business Acquisition Pro Forma Research And Development Expense
BusinessAcquisitionProFormaResearchAndDevelopmentExpense
1471000
nvus Business Acquisition Pro Forma General And Administrative Expense
BusinessAcquisitionProFormaGeneralAndAdministrativeExpense
5474000
nvus Business Acquisition Pro Forma Other Nonoperating Income Expense
BusinessAcquisitionProFormaOtherNonoperatingIncomeExpense
55000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
85000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
347611 shares
us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-27058000
us-gaap Business Acquisitions Pro Forma Income Loss From Continuing Operations Before Changes In Accounting And Extraordinary Items Net Of Tax
BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax
-27100000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2172000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
20000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.68
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
762000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-207000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-45000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
105000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-10000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2162000
us-gaap Operating Expenses
OperatingExpenses
2044000
us-gaap Net Income Loss
NetIncomeLoss
-2105000
us-gaap Operating Income Loss
OperatingIncomeLoss
-2044000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-61000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
10000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1282000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
77856 shares
nvus Business Acquisition Pro Forma Operating Expenses
BusinessAcquisitionProFormaOperatingExpenses
27100000
nvus Business Acquisitions Pro Forma Weighted Average Shares Outstanding Basic And Diluted
BusinessAcquisitionsProFormaWeightedAverageSharesOutstandingBasicAndDiluted
6605009 shares
nvus Number Of Milestones Achieved
NumberOfMilestonesAchieved
0 Milestone
nvus Business Acquisition Pro Forma Income Loss From Continuing Operations Before Changes In Accounting And Extraordinary Items Net Of Tax Per Share Basic And Diluted
BusinessAcquisitionProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTaxPerShareBasicAndDiluted
-4.10
nvus Interest Accumulated On Preferred Shares And Contingently Issuable For Little Or No Cash
InterestAccumulatedOnPreferredSharesAndContingentlyIssuableForLittleOrNoCash
459000
nvus Net Income Loss Attributable To Shareholders Of Preferred Shares And Contingently Issuable For Little Or No Cash
NetIncomeLossAttributableToShareholdersOfPreferredSharesAndContingentlyIssuableForLittleOrNoCash
2200000
nvus Net Loss Used In The Calculation Of Basic And Diluted Loss Per Share
NetLossUsedInTheCalculationOfBasicAndDilutedLossPerShare
-364000
nvus Business Acquisition Pro Forma Research And Development Expense
BusinessAcquisitionProFormaResearchAndDevelopmentExpense
19109000
nvus Business Acquisition Pro Forma General And Administrative Expense
BusinessAcquisitionProFormaGeneralAndAdministrativeExpense
7991000
nvus Business Acquisition Pro Forma Other Nonoperating Income Expense
BusinessAcquisitionProFormaOtherNonoperatingIncomeExpense
42000
CY2016 nvus Effective Federal And State Income Tax Rate
EffectiveFederalAndStateIncomeTaxRate
0.35 pure
CY2016Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
347611 shares
CY2016Q2 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-14528000
CY2016Q2 us-gaap Business Acquisitions Pro Forma Income Loss From Continuing Operations Before Changes In Accounting And Extraordinary Items Net Of Tax
BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax
-14507000
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.25
CY2016Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
340000
CY2016Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
46000
CY2016Q2 us-gaap Operating Expenses
OperatingExpenses
932000
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-1002000
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-932000
CY2016Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-70000
CY2016Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
592000
CY2016Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
77856 shares
CY2016Q2 nvus Business Acquisition Pro Forma Operating Expenses
BusinessAcquisitionProFormaOperatingExpenses
14507000
CY2016Q2 nvus Business Acquisitions Pro Forma Weighted Average Shares Outstanding Basic And Diluted
BusinessAcquisitionsProFormaWeightedAverageSharesOutstandingBasicAndDiluted
6605009 shares
CY2016Q2 nvus Business Acquisition Pro Forma Income Loss From Continuing Operations Before Changes In Accounting And Extraordinary Items Net Of Tax Per Share Basic And Diluted
BusinessAcquisitionProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTaxPerShareBasicAndDiluted
-2.20
CY2016Q2 nvus Interest Accumulated On Preferred Shares And Contingently Issuable For Little Or No Cash
InterestAccumulatedOnPreferredSharesAndContingentlyIssuableForLittleOrNoCash
229000
CY2016Q2 nvus Net Income Loss Attributable To Shareholders Of Preferred Shares And Contingently Issuable For Little Or No Cash
NetIncomeLossAttributableToShareholdersOfPreferredSharesAndContingentlyIssuableForLittleOrNoCash
1056000
CY2016Q2 nvus Net Loss Used In The Calculation Of Basic And Diluted Loss Per Share
NetLossUsedInTheCalculationOfBasicAndDilutedLossPerShare
-175000
CY2016Q2 nvus Business Acquisition Pro Forma Research And Development Expense
BusinessAcquisitionProFormaResearchAndDevelopmentExpense
10487000
CY2016Q2 nvus Business Acquisition Pro Forma General And Administrative Expense
BusinessAcquisitionProFormaGeneralAndAdministrativeExpense
4020000
CY2016Q2 nvus Business Acquisition Pro Forma Other Nonoperating Income Expense
BusinessAcquisitionProFormaOtherNonoperatingIncomeExpense
-21000
CY2017Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
587819 shares
CY2017Q2 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-3260000
CY2017Q2 us-gaap Business Acquisitions Pro Forma Income Loss From Continuing Operations Before Changes In Accounting And Extraordinary Items Net Of Tax
BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax
-3278000
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.32
CY2017Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6133000
CY2017Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
141000
CY2017Q2 us-gaap Operating Expenses
OperatingExpenses
6666000
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-6662000
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-6666000
CY2017Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4000
CY2017Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
533000
CY2017Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4154842 shares
CY2017Q2 nvus Business Acquisition Pro Forma Operating Expenses
BusinessAcquisitionProFormaOperatingExpenses
3278000
CY2017Q2 nvus Business Acquisitions Pro Forma Weighted Average Shares Outstanding Basic And Diluted
BusinessAcquisitionsProFormaWeightedAverageSharesOutstandingBasicAndDiluted
6943831 shares
CY2017Q2 nvus Business Acquisition Pro Forma Income Loss From Continuing Operations Before Changes In Accounting And Extraordinary Items Net Of Tax Per Share Basic And Diluted
BusinessAcquisitionProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTaxPerShareBasicAndDiluted
-0.47
CY2017Q2 nvus Interest Accumulated On Preferred Shares And Contingently Issuable For Little Or No Cash
InterestAccumulatedOnPreferredSharesAndContingentlyIssuableForLittleOrNoCash
98000
CY2017Q2 nvus Net Income Loss Attributable To Shareholders Of Preferred Shares And Contingently Issuable For Little Or No Cash
NetIncomeLossAttributableToShareholdersOfPreferredSharesAndContingentlyIssuableForLittleOrNoCash
1279000
CY2017Q2 nvus Net Loss Used In The Calculation Of Basic And Diluted Loss Per Share
NetLossUsedInTheCalculationOfBasicAndDilutedLossPerShare
-5481000
CY2017Q2 nvus Business Acquisition Pro Forma Research And Development Expense
BusinessAcquisitionProFormaResearchAndDevelopmentExpense
686000
CY2017Q2 nvus Business Acquisition Pro Forma General And Administrative Expense
BusinessAcquisitionProFormaGeneralAndAdministrativeExpense
2592000
CY2017Q2 nvus Business Acquisition Pro Forma Other Nonoperating Income Expense
BusinessAcquisitionProFormaOtherNonoperatingIncomeExpense
18000

Files In Submission

Name View Source Status
0001193125-17-252847-index-headers.html Edgar Link pending
0001193125-17-252847-index.html Edgar Link pending
0001193125-17-252847.txt Edgar Link pending
0001193125-17-252847-xbrl.zip Edgar Link pending
d406704d10q.htm Edgar Link pending
d406704dex101.htm Edgar Link pending
d406704dex102.htm Edgar Link pending
d406704dex103.htm Edgar Link pending
d406704dex104.htm Edgar Link pending
d406704dex105.htm Edgar Link pending
d406704dex106.htm Edgar Link pending
d406704dex107.htm Edgar Link pending
d406704dex311.htm Edgar Link pending
d406704dex312.htm Edgar Link pending
d406704dex321.htm Edgar Link pending
d406704dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g406704g0801121501193.jpg Edgar Link pending
g406704g48p06.gif Edgar Link pending
nvus-20170630.xml Edgar Link completed
nvus-20170630.xsd Edgar Link pending
nvus-20170630_cal.xml Edgar Link unprocessable
nvus-20170630_def.xml Edgar Link unprocessable
nvus-20170630_lab.xml Edgar Link unprocessable
nvus-20170630_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending